Press release
New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects Over 13 Million Americans Each Year: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.* Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* Completion of NDA Filing Expected in First Quarter of 2025
* Plans to Participate in J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA.
* Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials."
* Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide."
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has the potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for the development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.
Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression. The Company is now seeking to expand the indication to include Suicidal Ideation in Major Depressive Disorder and other forms of depression, based on data from NIH- and European Government-funded trials that have been summarized on the NRXP website.
While assembly of the clinical data sections is being completed, FDA has asked the Company to submit the 1800-page manufacturing section (Module 3) of the NDA to enable immediate review prior to submission of final efficacy data and other sections of the NDA expected in the first quarter of 2025.
The NRx presentation of ketamine differs from the form of ketamine used in anesthesia in that it contains no potentially toxic preservatives and utilizes diversion-resistant packaging to enhance the traceability of a medicine known to have abuse potential.
Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"
On November 25th NRXP announced the publication of a paper by Sapko, et. al. in the peer-reviewed American Journal of Clinical Psychopharmacology. The paper, entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials,"1 reported on the impact of a comprehensive program developed by NRx Pharmaceuticals to enhance reliability in psychometric ratings that are key to drug approval. Registration trials of drugs for depression and related conditions frequently fail because of unexpected statistical variability across study sites. NRx developed a methodology for training and monitoring the performance of the study site raters, whose measurements are key to the success or failure of all clinical trials of antidepressant drugs. This approach resulted in an unprecedented level of agreement (3 points or better on a 60-point scale) compared to prior industry practices.
In the NRX-101 study, trial concordance, as defined by no more than 3 points of disagreement between site raters and central raters, was seen in 94.5% of ratings, where standard industry practice was to accept substantially higher variance (i.e. up to 6 points of disagreement) between study site raters and central raters.2 Accepting higher variance entails recruiting many more participants to achieve statistical significance with substantially higher study costs and risks of failure. NRXP will be using this improved methodology in future drug development and clinical trials conducted within its network of HOPE clinics.
NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"
In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.
For more information on $NRXP visit: https://www.nrxpharma.com/ [about:blank] and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Disclaimer and Disclosure: www.aibrandnetwork.com [about:blank]
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email [http://www.universalpressrelease.com/?pr=new-drug-application-to-the-fda-for-the-treatment-of-suicidal-depression-that-affects-over-13-million-americans-each-year-nrx-pharmaceuticals-inc-stock-symbol-nrxp]
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Miami
State: Florida
Country: United States
Website: https://www.nrxpharma.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects Over 13 Million Americans Each Year: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) here
News-ID: 3801013 • Views: …
More Releases from Getnews
Dennis Farrah Calls for Greater Financial Literacy and Everyday Integrity in Acc …
The retired financial planner and Vietnam veteran urges Americans to take small, practical steps toward financial awareness and ethical responsibility.
After more than 40 years in financial planning and tax work, Dennis Mitchell Farrah [https://www.dennis-farrah.com/], a Vietnam-era veteran and longtime advocate for trust in accounting, is speaking out about the urgent need for financial literacy and everyday ethics in money management. His message is simple: people don't need to be accountants…
Bonito Beauty Bar: Toronto's Premier Destination for Camouflage Tattoo and Stret …
Image: https://www.globalnewslines.com/uploads/2025/10/1761683917.jpg
Bonito Beauty Bar: Toronto's Premier Destination for Camouflage Tattoo and Stretch Mark Removal
This comprehensive article explores Bonito Beauty Bar's expertise as Toronto's premier destination for camouflage tattoo and stretch mark removal treatments. The piece details advanced paramedical tattooing techniques that use custom-blended pigments to seamlessly conceal scars, burns, and pigment loss. It explains inkless revision therapy as a breakthrough stretch mark removal method that stimulates natural collagen production without…
Amy Motroni Helps Thousands of Moms Simplify Their Lives with Genius Mom Hacks
Image: https://www.globalnewslines.com/uploads/2025/10/facd44bc3244a031ac9d6f7b1273644c.jpg
Photo Courtesy: Dene Ogles
Amy Motroni, a certified life coach and author, has emerged as a leading voice in the parenting space, offering practical solutions to help overwhelmed moms regain control of their homes and routines. Through her platform, Genius Mom Hacks, Motroni has assisted over 12,000 mothers in discovering strategies to reduce stress and implement systems that make everyday tasks more manageable. Her personal journey, from feeling buried in…
Extended Family Home Care Continues Dedication to Offering Trusted Elder Home Ca …
Image: https://www.globalnewslines.com/uploads/2025/10/1761676452.jpg
Extended Family Home Care continues its dedication to offering trusted elder home care in Denver, CO, providing compassionate, personalized support to seniors and their families. Their commitment ensures every client receives the care and attention they deserve, allowing them to live with dignity and independence in the comfort of their own home.
Extended Family Home Care reaffirms its commitment to exceptional elder care in Denver, CO. The agency provides personalized…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
